Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Active Pharmaceutical Ingredient CDMO Market

Active Pharmaceutical Ingredient CDMO Market Share

Report ID: GMI9272
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Active Pharmaceutical Ingredient CDMO Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical and biotechnology companies, emergence of biosimilars and the growing demand for outsourcing services. Key players are engaging in strategic initiatives such as investment, collaboration, and partnerships with CDMOs for the manufacturing of APIs.

Active Pharmaceutical Ingredient CDMO Market Companies

Prominent players operating in the market are as mentioned below:

Ajinomoto Biopharma Services
Boehringer Ingelheim
Cambrex Corporation
Catalent, Inc.
CordenPharma International
Kymanox Corporation
Lonza AG
Primal Pharma Solutions
Recipharm AB
Samsung Biologics
Siegfried Holding AG
Thermo Fisher Scientific Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Active pharmaceutical ingredient CDMO market size was USD 101.4 billion in 2023 and is expected to register 6.6% CAGR from 2024-2032 owing to rising prevalence of chronic disease such as cancer, cardiovascular disease, diabetes, and various other related disease worldwide.

Active pharmaceutical ingredient CDMO industry from the chemical APIs segment reached USD 60 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to rise in the research and development activities by pharmaceutical and biotechnology companies.

The U.S. active pharmaceutical ingredient CDMO industry is expected to register 6.8% CAGR from 2024-2032 due to rise in the demand for specialty & biologic drugs and rising pharmaceutical companies in the country.

Catalent, Inc., CordenPharma International, Kymanox Corporation, Lonza AG, Primal Pharma Solutions, Recipharm AB, Samsung Biologics, Siegfried Holding AG, and Thermo Fisher Scientific Inc., are some of the major active pharmaceutical ingredient CDMO companies worldwide.